Cigarette Smoking and Clopidogrel Interaction

被引：0
作者：
Kristopher J. Swiger
Omair Yousuf
Kevin P. Bliden
Udaya S. Tantry
Paul A. Gurbel
机构：
[1] Johns Hopkins University School of Medicine,Sinai Center for Thrombosis Research
[2] Sinai Hospital of Baltimore,Sinai Center for Thrombosis Research
[3] Sinai Hospital of Baltimore,undefined
[4] Cardiac Catheterization Laboratory,undefined
来源：
Current Cardiology Reports | 2013年 / 15卷
关键词：
Clopidogrel; Dual antiplatelet therapy; Acute coronary syndrome; Tobacco use; Smoking; Percutaneous revascularization; Adenosine diphosphate receptor antagonist; Prasugrel; Ticagrelor; High on-treatment platelet reactivity; Percutaneous coronary intervention;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Dual antiplatelet therapy (DAPT) with aspirin and an adenosine diphosphate receptor antagonist is central to the modern management of acute coronary syndromes and percutaneous revascularization. The most widely used adenosine diphosphate receptor antagonist, clopidogrel therapy is limited by inter-individual variability in platelet inhibition. Recent data suggest a potential role of smoking in the metabolism of clopidogrel and high on-treatment platelet reactivity. Pharmacodynamic studies and post-hoc analyses of large clinical trials support a link between smoking status and the efficacy of clopidogrel therapy. The mechanism of the interaction between smoking status and clopidogrel efficacy remains unclear but may be mediated by cytochrome P450 (CYP)1A2. There is less evidence available on the influence of smoking status on platelet reactivity and clinical outcomes during prasugrel and ticagrelor therapy.
引用
收藏
相关论文
共 354 条
  • [11] Bliden KP(2009)Smoking promotes clopidogrel-mediated platelet inhibition in patients receiving dual antiplatelet therapy Thromb Res 124 588-108
  • [12] Hiatt BL(2009)Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention Am J Cardiol 103 1339-6
  • [13] O’Connor CM(2009)Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin’s advantage and the smoking “paradox” J Cardiovasc Pharmacol 53 368-44
  • [14] Gurbel PA(2010)Slow response to clopidogrel predicts low response J Am Coll Cardiol 55 815-8
  • [15] Antonino MJ(2010)Smoking at least 10 cigarettes per day increases platelet inhibition by clopidogrel in patients with ST-segment-elevation myocardial infarction Thromb Res 126 e334-43
  • [16] Tantry US(2011)The effect of ticagrelor vs clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies Am Heart J 162 160-22
  • [17] Matetzky S(2011)Enhanced clopidogrel responsiveness in smokers: smokers’ paradox is dependent on cytochrome P450 CYP1A2 status Arterioscl Thromb Vasc Biol 31 665-64
  • [18] Shenkman B(2008)Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation Anal Bioanal Chem 392 1093-23
  • [19] Guetta V(2012)Clopidogrel efficacy and cigarette smoking status JAMA 307 2495-6
  • [20] Shechter M(2009)Smoking, clopidogrel, and mortality in patients with established cardiovascular disease Circulation 120 2337-47
12345678910